English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

PERSISTENT hyperinsulinemic hypoglycemia of infancy is a disease characterized clinically by persistent hypoglycemia with inappropriately high circulating insulin concentrations. Nesidioblastosis is a diffuse abnormality of the pancreas in which there is extensive, often disorganized formation of new islets, and is known to cause hyperinsulinemic hypoglycemia [1, 2]. Diazoxide can suppress hyperinsulinemia but has serious side effects [3]. Successful treatment with octreotide, a long-acting somatostatin analogue, was reported but it involves the possibility of suppresion of GH [4-6]. Here we report a case of persistent hyperinsulinemic hypoglycemia in a male infant who was treated by continuous subcutaneous injection of octreotide for 4 months, and on the course of his growth and development.

endocrine journal

Normal Growth after Administration of Octreotide: Report on a Case of Persistent Hyperinsulinemic Hypoglycemia of Infancy Treated by Continuous Subcutaneous Injection of Octreotide